Regeneron Pharmaceuticals, Inc.
REGN Healthcare Biotechnology
Regeneron Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, up 0.99% from fiscal 2024.
- Revenue
- +36.3%
- EPS
- +36.0%
- Free cash flow
- +3.85%
- Total debt
- −26.6%
Quarter to September 2026, against a year earlier
Follow REGN
Alert me
Regeneron Pharmaceuticals, Inc. (REGN) P/B ratio
As of 5 November 2026, Regeneron Pharmaceuticals, Inc. (REGN) trades at a P/B ratio of 2.7×. Over the past ten years it has ranged from 1.8× (June 2025) to 19.3× (March 2015); the current reading is higher than 16% of that period. That is above the Biotechnology industry median of 2.0× and above the Healthcare sector median of 2.3×.
P/B ratio, daily
Embed this chart
Annual newest first
| Period | P/B ratio | Change |
|---|---|---|
| FY2025 | 2.6× | (1.35%) |
| FY2024 | 2.6× | (29.57%) |
| FY2023 | 3.7× | 9.20% |
| FY2022 | 3.4× | (4.27%) |
| FY2021 | 3.6× | (24.57%) |
| FY2020 | 4.7× | 27.52% |
| FY2019 | 3.7× | (19.66%) |
| FY2018 | 4.6× | (30.48%) |
| FY2017 | 6.6× | (25.92%) |
| FY2016 | 8.9× | (41.63%) |
Quarterly newest first
| Period | P/B ratio | Change |
|---|---|---|
| Sep 2026 | 2.3× | 13.89% |
| Jun 2026 | 2.0× | (20.95%) |
| Mar 2026 | 2.6× | (1.00%) |
| Dec 2025 | 2.6× | 37.28% |
| 43 more quarters | Free account |
Against its own ten years
P/B ratio against peers
| Company | P/B ratio |
|---|---|
| REGN Regeneron Pharmaceuticals, Inc. | 2.7× |
| RPRX Royalty Pharma PLC compare | 3.1× |
| ROIV Roivant Sciences Ltd. compare | 5.4× |
| GMAB Genmab A/S Sponsored ADR compare | 5.5× |
| VRTX Vertex Pharmaceuticals Incorporated compare | 6.6× |
| ARGX argenex SE compare | 6.7× |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 7.5× |
| MRNA Moderna, Inc. compare | 14.2× |
| RVMD Revolution Medicines, Inc. compare | 16.1× |
| Biotechnology industry median | 2.0× |
| Healthcare sector median | 2.3× |
| Market median | 1.7× |
What P/B ratio is
Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.
Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))
More on REGN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement